These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34784617)

  • 21. Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention.
    Garcia SM; Kellom KS; Boelig RC; Wang X; Matone M
    Womens Health Rep (New Rochelle); 2021; 2(1):295-304. PubMed ID: 34327511
    [No Abstract]   [Full Text] [Related]  

  • 22. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
    Zhang S; Rascati KL
    Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
    Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
    Cross-Barnet C; Benatar S; Courtot B; Hill I; Johnston E; Cheeks M
    Matern Child Health J; 2018 Nov; 22(11):1607-1616. PubMed ID: 29956128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
    González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB
    Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.
    Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW;
    BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivering equity: preterm birth by socioeconomic class before and after coverage of 17-hydroxyprogesterone caproate.
    Hesson AM; Pitts DS; Langen ES
    J Matern Fetal Neonatal Med; 2022 Dec; 35(24):4713-4716. PubMed ID: 33430664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
    DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
    Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
    Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
    Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
    Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
    Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
    Hydery T; Price MK; Greenwood BC; Takeshita M; Kunte PS; Mauro RP; Lenz K; Jeffrey PL
    Pharmacotherapy; 2017 Oct; 37(10):1328-1334. PubMed ID: 28833362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.